Management of Severe Anemia

Immediate Assessment and Transfusion Decision

The critical threshold for transfusion consideration is hemoglobin <7.5 g/dL, particularly when accompanied by clinical symptoms or hemodynamic instability 1
Symptomatic anemia (fatigue, dyspnea, chest pain, tachycardia, hypotension) is an indication for transfusion 1
Hemodynamic instability is an indication for transfusion 1
Comorbidities including ischemic heart disease, older age, or other significant medical conditions increase the need for transfusion 1
Transfuse 2-3 units of packed red blood cells to manage the acute episode 1
Each unit of packed red blood cells should raise hemoglobin by approximately 1.5 g/dL (400 mL packed cells) 1
Avoid transfusing excessive volumes that could lead to circulatory overload, particularly in patients with cardiac or renal disease 1

Complete blood count with reticulocyte count should be conducted to assess bone marrow response 2
Iron studies (ferritin, transferrin saturation) should be conducted to assess for functional iron deficiency 3, 1
Vitamin B12 and folate levels should be checked 2
Inflammatory markers should be assessed to evaluate for chronic disease 2
Renal function (creatinine, eGFR) should be evaluated 2
Peripheral blood smear examination should be conducted 2
Coombs testing should be conducted if patient has CLL, NHL, or autoimmune disease history 2

For cancer patients on chemotherapy, erythropoiesis-stimulating agents (ESAs) should only be initiated if hemoglobin <10 g/dL with at least 2 additional months of planned chemotherapy 3, 2
For cancer patients on chemotherapy, transfuse first to stabilize the patient, then consider ESA therapy after transfusion if chemotherapy is ongoing 1, 4
For cancer patients on chemotherapy, target hemoglobin should not exceed 12 g/dL, as higher targets increase mortality risk 3, 4
For chronic kidney disease patients, initiate treatment when hemoglobin <10 g/dL, and correct iron deficiency first by ensuring ferritin >100 ng/mL and transferrin saturation >20% 3, 1
For hepatitis C patients on triple therapy, transfusion is indicated at hemoglobin <7.5 g/dL with symptoms or lack of response to other measures 1
For myelodysplastic syndrome, ESAs can be used off-label in low-risk MDS, starting at 450 IU/kg/week for at least 8-10 weeks 3, 5

ESAs are contraindicated in cancer patients not receiving chemotherapy due to increased mortality risk 3, 6, 4
Avoid ESAs entirely if patient has uncontrolled hypertension, or history of pure red cell aplasia from ESAs 3, 6